NAGIOS: RODERIC FUNCIONANDO

Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies:a systematic review and meta-analysis

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies:a systematic review and meta-analysis

dc.contributor.author	Salgado Peralvo, Ángel Orión	es
dc.contributor.author	Montero-Alonso, María	es
dc.contributor.author	Kewalramani Kewalramani, Naresh	es
dc.contributor.author	Pérez-Sayáns, Mario	es
dc.contributor.author	Mateos Moreno, María Victoria	es
dc.contributor.author	Garcillán Izquierdo, María del Rosario	es
dc.date.accessioned	2023-06-16T08:36:52Z
dc.date.available	2023-06-16T08:36:52Z
dc.date.issued	2022	es
dc.identifier.citation	Salgado-Peralvo, AO., Montero-Alonso, M., Kewalramani, N., Pérez-Sayáns-García, M., Mateos-Moreno, MV., & Garcillán-Izquierdo, MR. (2022). Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis. En Medicina Oral Patología Oral y Cirugia Bucal (pp. e588-e599). Medicina Oral, S.L. https://doi.org/10.4317/medoral.25528	es
dc.identifier.uri	https://hdl.handle.net/10550/88165
dc.description.abstract	Currently, the most frequently employed therapies in the treatment of inflammatory bowel diseases (IBD), i.e., Crohn's Disease (CD), Ulcerative Colitis (UC) or unclassified IBD (IBD-U) are monoclonal anti-TNFs and anti-integrin therapies, such as vedolizumab (VDZ). Forty-seven per cent of these patients present extra-intestinal manifestations, the second most prevalent being aphthous stomatitis (AS). The present study aims to investigate which of the two therapies is associated with a lower prevalence of AS after treatment. An electronic search of the MEDLINE (via PubMed), Web of Science, SCOPUS, LILACS and OpenGrey databases was carried out. The criteria used were those described by the PRISMA Statement. The search was not temporarily restricted and was updated to January 2022. The quality assessment was analyzed using the JBI Prevalence Critical Appraisal Tool. After searching, 7 studies were included that met the established criteria. Of these, 6 analysed the prevalence of AS in CD patients and 4 in UC. A total of 1,744 patients were analysed (CD=1,477 patients; 84.69%; UC=267; 15.31%). The greatest reduction in AS prevalence was observed after anti-TNF therapy. The effect of these therapies on the prevalence of AS in patients with IBD-U could not be determined. Both biologic therapies achieve a reduction in the prevalence of AS in IBD patients (CD and UC). However, the best results were obtained in patients treated with anti-TNFs, possibly because VDZ is often used in patients who do not respond adequately to previous treatment with anti-TNFs and because of its intestinal specificity.	es
dc.subject	oral cancer	es
dc.subject	hospitalization	es
dc.subject	spatial analysis	es
dc.subject	death	es
dc.title	Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies:a systematic review and meta-analysis	es
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO:CIENCIAS MÉDICAS	es
dc.identifier.doi	10.4317/medoral.25528	es
dc.type.hasVersion	VoR	es_ES
dc.identifier.url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648636/